Journals / TSK Koruyucu Hekimlik Bülteni / 2014 / Cilt: 13 - Sayı: 1

A Public Health Issue that Increased Prevelance: Non-Acholic Fatty Liver Disease

Sıklığı Artan Bir Halk Sağlığı Sorunu: Non-Alkolik Yağlı Karaciğer Hastalığı

Pages
65–76
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Nutrition regulations and slow and continuous weight loss with regular exercises is still best treatment method

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Non-alcoholic fatty liver disease (NAFLD), is a liver disease, that occur in non alcohol users, with same histological features of alcoholic liver disease.
📊
Key Findings & Data:The increased importance of NAFLD is depends on its close relation of current problems such as Type 2 Diabetes Mellitus and hyperlipidemia, and its high prevalence as %20-30, in Europe and Middle East.
💡
Conclusion & Impact:Nutrition regulations and slow and continuous weight loss with regular exercises is still best treatment method
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Non-alcoholic fatty liver disease (NAFLD), is a liver disease, that occur in non alcohol users, with same histological features of alcoholic liver disease. The increased importance of NAFLD is depends on its close relation of current problems such as Type 2 Diabetes Mellitus and hyperlipidemia, and its high prevalence as %20-30, in Europe and Middle East. NAFLD has a wide spectrum from simple steatozis (SS), liver cell damage, non alcoholic steatohepatitis (NASH) with inflammation to high stage fibrosis, and cirrhosis. Hepathocellular cancer and liver failure might develop in cirrhosis patients. Biopsy is gold standard for NAFLD diagnosis; differentiate from SS and NASH and defining NASH stages. Nutrition regulations and slow and continuous weight loss with regular exercises is still best treatment method

Özet

Non-alkolik yağlı karaciğer hastalığı (NAYKH), alkol almayan kişiler de alkole bağlı yağlı karaciğer hastalığının histolojik özellikleri ile birlikte olan bir karaciğer hastalığıdır. Tip 2 diabetes mellitus (Tip2 DM), hiperlipidemi ve obezite gibi güncel sorunlarla yakın ilişkisi, Avrupa ve Ortadoğuda %20-30 gibi yüksek bir prevalansa sahip olması, NAYKH üzerine odaklanılmasına yol açmıştır. Basit yağlanmadan (SS) karaciğer hücre yaralanması ve inflamasyonun birlikte olduğu non-alkolik steatohepatit (NASH), ilerlemiş fibrozis ve siroza kadar geniş spektrumlu bir karaciğer hasarını tanımlar. İlerlemiş sirozu olanlarda daha nadir olarak hepatosellüler kanser veya karaciğer yetmezliği gelişebilir. NAYKH tanısı, SS ile NASH ayırımında ve NASH evreleme ve derecelendirmesinde altın standart karaciğer biyopsisidir. Uygun beslenme ve düzenli egzersiz yaparak yavaş ve devamlı kilo kaybının sağlanması hala en etkili tedavi yöntemidir

🔖

Cite This Article

KARA, M., ERDAL, M. (2014). A Public Health Issue that Increased Prevelance: Non-Acholic Fatty Liver Disease. TSK Koruyucu Hekimlik Bülteni, Cilt: 13 - Sayı: 1, 65–76. https://ajindex.com/articles/126007

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. 1Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007; 191: 235-240. 2Baumeister SE, Volzke H, Marschall P, et al. Impact of fatty liver disease on health care utilization and costs ina general population: a 5-year observation. Gastroenterology. 2008; 134: 85-94. 3 Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55: 434-438. 4Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346: 1221-1231. 5 Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001; 21: 27-41 6 Dixon JB, Bhathal PS, Hughes NR, et al. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology. 2004; 39: 1647-1654. 7 Neuschwander-Tetri BA, Cadwell SH. Nonalcoholic steatohepatitis: Summary of a AASLD single topic conference. Hepatology. 2003; 37: 1202-1219. 8 Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002; 123: 745-750. 9 Teli MR, James OF, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995; 22: 1714-1719. 10 Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000; 132: 112-117. 11 Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008; 134: 416-423. 12Powell EE, Ali A, Clouston AD, et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology. 2005; 129: 1937-1943. 13 Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology. 2005; 42: 5-13. 14 Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 7. [Epub ahead of print]. 15 Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005; 42: 44-52. 16 Zelber-SagiS, Nitzan-Kaluski D, Halpern Z, et al. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int. 2006; 26: 856-863. 17Fan